Endoscopic ultrasound and PDT for pancreatic cancer

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Background and Aims: In a single-center, prospective, dose-escalation phase 1 study, patients with treatment-naïve locally advanced pancreatic cancer (LAPC) received intravenous porfimer sodium followed 2 days later by EUS-PDT. EUS-PDT was performed by puncture with a 19-gauge needle and insertion of a 1.0-cm light diffuser and illumination with a 630-nm light. A CT scan 18 days after PDT was done to assess for change in pancreatic necrosis. Nab-paclitaxel and gemcitabine were initiated 7 days after CT. Results: Twelve patients (mean age, 67 ± 6 years; 8 male) with tumors (mean diameter, 45.2 ± 12.9 mm) in the head and/or neck (8) or body and/or tail (4) underwent EUS-PDT. Compared with baseline imaging, increased volume and percentage of tumor necrosis were observed in 6 of 12 patients (50%) after EUS-PDT. No serious adverse events from PDT occurred. Conclusion: EUS-PDT for LAPC is technically feasible. Phase II studies are warranted.

Original languageEnglish (US)
Title of host publication17th International Photodynamic Association World Congress
EditorsTayyaba Hasan
PublisherSPIE
ISBN (Electronic)9781510628335
DOIs
StatePublished - Jan 1 2019
Event17th International Photodynamic Association World Congress 2019 - Cambridge, United States
Duration: Jun 28 2019Jul 4 2019

Publication series

NameProceedings of SPIE - The International Society for Optical Engineering
Volume11070
ISSN (Print)0277-786X
ISSN (Electronic)1996-756X

Conference

Conference17th International Photodynamic Association World Congress 2019
CountryUnited States
CityCambridge
Period6/28/197/4/19

Fingerprint

Necrosis
Ultrasound
Tumors
Tumor
Cancer
necrosis
Ultrasonics
cancer
Diffuser
Computerized tomography
tumors
Sodium
Needles
Gages
Insertion
Percentage
Illumination
Tail
Baseline
Dose

ASJC Scopus subject areas

  • Electronic, Optical and Magnetic Materials
  • Condensed Matter Physics
  • Computer Science Applications
  • Applied Mathematics
  • Electrical and Electronic Engineering

Cite this

Dewitt, J. (2019). Endoscopic ultrasound and PDT for pancreatic cancer. In T. Hasan (Ed.), 17th International Photodynamic Association World Congress [110705Y] (Proceedings of SPIE - The International Society for Optical Engineering; Vol. 11070). SPIE. https://doi.org/10.1117/12.2528591

Endoscopic ultrasound and PDT for pancreatic cancer. / Dewitt, John.

17th International Photodynamic Association World Congress. ed. / Tayyaba Hasan. SPIE, 2019. 110705Y (Proceedings of SPIE - The International Society for Optical Engineering; Vol. 11070).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Dewitt, J 2019, Endoscopic ultrasound and PDT for pancreatic cancer. in T Hasan (ed.), 17th International Photodynamic Association World Congress., 110705Y, Proceedings of SPIE - The International Society for Optical Engineering, vol. 11070, SPIE, 17th International Photodynamic Association World Congress 2019, Cambridge, United States, 6/28/19. https://doi.org/10.1117/12.2528591
Dewitt J. Endoscopic ultrasound and PDT for pancreatic cancer. In Hasan T, editor, 17th International Photodynamic Association World Congress. SPIE. 2019. 110705Y. (Proceedings of SPIE - The International Society for Optical Engineering). https://doi.org/10.1117/12.2528591
Dewitt, John. / Endoscopic ultrasound and PDT for pancreatic cancer. 17th International Photodynamic Association World Congress. editor / Tayyaba Hasan. SPIE, 2019. (Proceedings of SPIE - The International Society for Optical Engineering).
@inproceedings{ecc28bb9b72a431a9db97f6ec71a3233,
title = "Endoscopic ultrasound and PDT for pancreatic cancer",
abstract = "Background and Aims: In a single-center, prospective, dose-escalation phase 1 study, patients with treatment-na{\"i}ve locally advanced pancreatic cancer (LAPC) received intravenous porfimer sodium followed 2 days later by EUS-PDT. EUS-PDT was performed by puncture with a 19-gauge needle and insertion of a 1.0-cm light diffuser and illumination with a 630-nm light. A CT scan 18 days after PDT was done to assess for change in pancreatic necrosis. Nab-paclitaxel and gemcitabine were initiated 7 days after CT. Results: Twelve patients (mean age, 67 ± 6 years; 8 male) with tumors (mean diameter, 45.2 ± 12.9 mm) in the head and/or neck (8) or body and/or tail (4) underwent EUS-PDT. Compared with baseline imaging, increased volume and percentage of tumor necrosis were observed in 6 of 12 patients (50{\%}) after EUS-PDT. No serious adverse events from PDT occurred. Conclusion: EUS-PDT for LAPC is technically feasible. Phase II studies are warranted.",
author = "John Dewitt",
year = "2019",
month = "1",
day = "1",
doi = "10.1117/12.2528591",
language = "English (US)",
series = "Proceedings of SPIE - The International Society for Optical Engineering",
publisher = "SPIE",
editor = "Tayyaba Hasan",
booktitle = "17th International Photodynamic Association World Congress",

}

TY - GEN

T1 - Endoscopic ultrasound and PDT for pancreatic cancer

AU - Dewitt, John

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background and Aims: In a single-center, prospective, dose-escalation phase 1 study, patients with treatment-naïve locally advanced pancreatic cancer (LAPC) received intravenous porfimer sodium followed 2 days later by EUS-PDT. EUS-PDT was performed by puncture with a 19-gauge needle and insertion of a 1.0-cm light diffuser and illumination with a 630-nm light. A CT scan 18 days after PDT was done to assess for change in pancreatic necrosis. Nab-paclitaxel and gemcitabine were initiated 7 days after CT. Results: Twelve patients (mean age, 67 ± 6 years; 8 male) with tumors (mean diameter, 45.2 ± 12.9 mm) in the head and/or neck (8) or body and/or tail (4) underwent EUS-PDT. Compared with baseline imaging, increased volume and percentage of tumor necrosis were observed in 6 of 12 patients (50%) after EUS-PDT. No serious adverse events from PDT occurred. Conclusion: EUS-PDT for LAPC is technically feasible. Phase II studies are warranted.

AB - Background and Aims: In a single-center, prospective, dose-escalation phase 1 study, patients with treatment-naïve locally advanced pancreatic cancer (LAPC) received intravenous porfimer sodium followed 2 days later by EUS-PDT. EUS-PDT was performed by puncture with a 19-gauge needle and insertion of a 1.0-cm light diffuser and illumination with a 630-nm light. A CT scan 18 days after PDT was done to assess for change in pancreatic necrosis. Nab-paclitaxel and gemcitabine were initiated 7 days after CT. Results: Twelve patients (mean age, 67 ± 6 years; 8 male) with tumors (mean diameter, 45.2 ± 12.9 mm) in the head and/or neck (8) or body and/or tail (4) underwent EUS-PDT. Compared with baseline imaging, increased volume and percentage of tumor necrosis were observed in 6 of 12 patients (50%) after EUS-PDT. No serious adverse events from PDT occurred. Conclusion: EUS-PDT for LAPC is technically feasible. Phase II studies are warranted.

UR - http://www.scopus.com/inward/record.url?scp=85075903499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075903499&partnerID=8YFLogxK

U2 - 10.1117/12.2528591

DO - 10.1117/12.2528591

M3 - Conference contribution

AN - SCOPUS:85075903499

T3 - Proceedings of SPIE - The International Society for Optical Engineering

BT - 17th International Photodynamic Association World Congress

A2 - Hasan, Tayyaba

PB - SPIE

ER -